BNP Paribas Maintains Neutral on Medline, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 76.2%

Neg 76.2% Neu 0% Pos 0%

BNP Paribas analyst Navann Ty maintains Medline (NASDAQ:MDLN) with a Neutral and lowers the price target from $49 to $40.